ALTA 002
Alternative Names: ALTA-002; Anti-SIRPa antibody conjugated toll-like receptor 9 agonists - ALX Oncology/Tallac Therapeutics; TAC-002Latest Information Update: 14 Aug 2023
At a glance
- Originator ALX Oncology; Tallac Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Oligonucleotides
- Mechanism of Action SIRPA protein inhibitors; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Aug 2023 Tallac Therapeutics intends to file an investigational new drug (IND) application for ALTA 002 in first quarter of 2024
- 23 Mar 2021 Preclinical trials in Cancer in USA (unspecified route) prior to March 2021
- 04 Mar 2021 ALX Oncology and Tallac Therapeutics co-develop ALTA 002 for Cancer in USA